Caribou Biosciences, Inc. (CRBU)
Develops cancer-fighting cell therapies using CRISPR gene-editing technology.
$1.49-0.06%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-23.6%
The outlook
CRBU trades at $1.49, well below both its 50- and 200-day moving averages and near its 52-week low. Analyst coverage shows a wide gap—the average price target sits roughly 7× the current price—though the stock's overall sentiment leans bearish. The data reflects a deeply depressed valuation against analyst expectations, signaling significant disagreement about the company's near-term direction.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range5% of the way from its 52-week low to high
Price targetAvg target +705% vs current price
Analyst price target
~12-month · 7 analysts$12.00average target+705.4% vs now
Now $1.49
Low $4.00High $32.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$147.8M
52-wk high
$3.54
52-wk low
$1.38
50-day avg
$1.86
200-day avg
$1.91
Trailing P/E
—